Efsubaglutide Alfa
Sources
registry, as of 2026-01-30Stale
https://clinicaltrials.gov/study/NCT06921486
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2,PHASE3. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 1003. Conditions Obesity and Overweight. This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoin
ClinicalTrials.gov NCT06921486 protocol and results modules
registry, as of 2025-12-02Stale
https://clinicaltrials.gov/study/NCT07114419
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE). Overall status RECRUITING. Phases PHASE2. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 200. Conditions Obesity and Overweight. This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, w
ClinicalTrials.gov NCT07114419 protocol and results modules
registry, as of 2025-04-02Stale
https://clinicaltrials.gov/study/NCT06732960
A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 50. Conditions Overweight or Obesity. This is a study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa at difference dose range once-weekly in patients with Overweight or Obesity.
ClinicalTrials.gov NCT06732960 protocol and results modules
registry, as of 2026-01-27Stale
https://clinicaltrials.gov/study/NCT07163650
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery. Overall status RECRUITING. Phases PHASE4. Lead sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Enrollment 60. Conditions Obesity; Weight Loss; Metabolic Surgery. This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
ClinicalTrials.gov NCT07163650 protocol and results modules
registry, as of 2026-07-30Stale
https://clinicaltrials.gov/study/NCT07693426
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents. Overall status RECRUITING. Phases PHASE1. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 36. Conditions Adolescence Obesity. This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with ob
ClinicalTrials.gov NCT07693426 protocol and results modules
publication, as of 2026-10-13Stale
https://pubmed.ncbi.nlm.nih.gov/42870102/
Efsubaglutide Alfa: A Comprehensive Pharmacological Review. Efsubaglutide alfa (also known as supaglutide) is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) engineered as a GLP-1 analogue fused to a human immunoglobulin G2 (IgG2) fragment crystallisable (Fc) domain. This narrative review summarises published and publicly ava
PMID 42870102